| Date | Title | Description |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 02.05.2024 | Genomenon Partners with Pharming to Advance APDS Diagnosis | Genomenon Logo
Genomenon Making Variant Data on the PIK3CD and PIK3R1 Genes Available to Genetic Testing Labs Across the World
ANN ARBOR, Mich., May 2, 2024 /PRNewswire-PRWeb/ -- Genomenon, a genomic intelligence company, has partnered with... |
| 14.03.2024 | Pharming Group reports fourth quarter and full year 2023 financial results | - |
| 14.03.2024 | Pharming Group reports fourth quarter and full year 2023 financial results | Full year 2023 total revenues increased by 19% to US$245.3 million
Record fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to US$227.1 million
Strong start to Joenja® (leni... |
| 09.08.2023 | Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan | Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency
LEIDEN, The Netherlands, Aug. 9, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or &quo... |
| 11.04.2023 | Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S. | LEIDEN, Netherlands, April 11, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces the first commercial shipments of Joenja® (leniolisib) to patients in the United States. Joe... |
| 25.03.2023 | Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS | APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency
Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older
Joenja® is expected to l... |
| 24.03.2023 | Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS | APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency
Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older
Joenja® is expected to l... |
| 21.02.2023 | Pharming announces first patient enrolled in pediatric clinical trial of leniolisib | The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency
LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or &qu... |
| 16.02.2023 | Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe | EMA Marketing Authorisation Application for leniolisib changed to standard review timetable
LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)... |
| 15.12.2022 | Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition | V. Koneti Rao, MD, shared new evidence of long-term safety and hematologic response in patients who received leniolisib to treat APDS, a rare primary immunodeficiency
Interim analysis demonstrated leniolisib to be well tolerated and indicat... |
| 07.12.2022 | Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood | Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency
The peer-reviewed publication heightens internati... |
| 28.10.2022 | Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib | Marketing authorisation in the European Economic Area anticipated in H1 2023
LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR)... |
| 11.10.2022 | Pharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib | Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency
This submission follows the grant of accelerated assessment allowing an expedited review for... |
| 28.09.2022 | Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib | The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency
LEIDEN, The Netherlands, Sep... |
| 02.08.2022 | Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency | Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts
LEIDEN, Netherlands, Aug. 2, 2022 /PRNewswire/ -- Pharming Group N.V. (&q... |
| 01.08.2022 | Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS | EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days
Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022
LEIDEN, the Netherlands, Aug. 1, ... |
| 01.04.2022 | Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting | LEIDEN, Netherlands, April 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces new data from the pivotal Phase II/III trial of leniolisib for the t... |
| 02.02.2022 | 4SC pulls plug on domatinostat; Pharming says leniolisib meets both endpoints | The management board of 4SC has discontinued its domatinostat program after the most recent clinical data has been released, the company announced Tuesday.
The orally administered small molecule class I selective inhibitor was being develop... |
| 14.09.2021 | Pharming N : announces results from clinical trials for the treatment of COVID-19 with RUCONEST® | Pharming announces results from clinical trials for the treatment of
COVID-19 with RUCONEST®
Pharming-sponsored study in US met primary endpoint
RUCONEST®-treated patients having statistically significant lower disease severity scores
(p=0.... |
| 20.07.2021 | Pharming N : signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa | Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
Leiden, The Netherlands, 20 July 2021: Pharming Group N.V. ("Pharming" or "the Company") ... |
| 23.06.2021 | Pharming N : announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome | Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (... |
| 04.06.2021 | PHARMING GROUP N.V.
Pharming N : announces the reimbursement of RUCONEST® in Spain | Pharming Group announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain.
Download full press releaseEN
Download volledig persberichtNL
We are delighted wi... |
| 01.06.2021 | PHARMING GROUP N.V.
Pharming N : Group to present at Jefferies Virtual Healthcare Conference | Pharming Group announces that its Chief Executive Officer, Sijmen de Vries, will present at the Jefferies Virtual Healthcare Conference 2021 at 14:30-14:55 CET/08:30-08:55 EDT on 4 June 2021.
Download full press releaseEN
Download volledig ... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 13.03.2020 | CureVac’s Ingmar Hoerr tells us why he returned to take on a pandemic; NGM loses a president | Ingmar Hoerr
On Tuesday, Ingmar Hoerr stood up from his seat at the head of CureVac’s board of directors meeting in Frankfurt, Germany and walked out the door.
For 18 years, Hoerr had led the company he founded, stewardin... |
| 19.09.2018 | UK advises against covering Novartis' Kymriah for adults; Ex-Mast chief Brian Culley appointed CEO at BioTime | → Right on the heels of endorsing the use of Novartis’ CAR-T Kymriah in children, the UK drug price watchdog NICE is turning its thumbs down for extending its welcome to adults. “However, NICE does recognise that Novartis’ ... |
| 09.08.2005 | Pharming gets Japanese patent on human lactoferrin | The patent covers the production and purification of the lactoferrin using the Pharming's technology as well as the substance's use in food formulations.
In Japan, bovine lactoferrin is currently used as an additive in food products as well... |
| 14.07.2005 | Pharming announces research collaboration with Novathera | Pharming announces research collaboration with Novathera
14-07-2005
Leiden, The Netherlands, July 12, 2005.
Pharming Group N.V. ('Pharming' or 'the Company') (Euronext: PHARM) (PHARM.AS) announced today a research collaboration with NovaThe... |
